Friday Satellite Symposia

Friday Satellite Symposia

Friday Satellite Symposia (FSS) are industry-supported, CME-certified symposia. These sessions are not part of the official ASH annual meeting program and are planned solely by the sponsoring company.

The 2023 FSS will be held on Friday, December 8. Each symposium will be presented once according to the program schedule and offers free registration. To register, click the “Registration” button below each title in the FSS program schedule. Check back as registration links will continue to be added as managing companies share them with ASH. For program-specific questions, please reach out to the managing company contact listed below each FSS session.

Please note, most, but not all sessions have a virtual component, and only some will be available on the annual meeting virtual platform. However, all sessions with a virtual component will be available (here) on the ASH website via the individual listings. Please review each listing carefully.

ASH appreciates its corporate and nonprofit partners for their participation in FSS. The Society values its partnerships and the supportive role that members of this community play in an effort to provide hematologists with quality educational programs. For more information, please review the 2023 FSS guidelines or contact Kelly Cade, Grants and Satellite Symposia Manager, Consultant, at [email protected].

65th ASH Annual Meeting Registration

San Diego Convention Center

Registration is now open for members, non-members, groups, exhibitors, and media!

View Registration Information

  • 1

    Morning Symposia

    7:00 a.m. - 10:00 a.m.
    Pacific time

    Advances in the Treatment Paradigm of Myeloid Malignancies: From Biology to Clinical Practice

    This program is supported by Cleveland Clinic and The Aplastic Anemia and MDS International Foundation


    7:00 a.m. - 10:00 a.m. Pacific time
    San Diego Convention Center
    Room 6CF

    The Cleveland Clinic Center for Continuing Medical Education, Cleveland Clinic Taussig Cancer Institute, and the Aplastic Anemia and MDS International Foundation, Inc. (AAMDSIF) join together to present a live and enduring continuing medical education activity focusing on clonal hematopoiesis, low and high risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN), aplastic anemia and paroxysmal nocturnal hemoglobinuria (AA & PNH) and cellular therapies for AML.

    This CME-certified activity will provide an in-depth and up-to-date review of research related to the biology, prognosis, natural history, and therapeutic management of patients with myeloid malignancies including AA, PNH, MDS, AML, MPN and related myeloid malignancies. The overall goal of the program is to bring together leaders in disease research and clinical practice to explore solutions to improving the care of these patient populations.

    Chair:

    Sudipto Mukherjee , MD, PhD, MPH
    Cleveland Clinic
    Cleveland,  OH

    Speakers:

    Uma M. Borate , MBBS, MS
    The Ohio State University Comprehensive Cancer Center
    Columbus,  OH

    Marco Davila , MD, PhD
    Roswell Park Comprehensive Cancer Center
    Buffalo,  NY

    Austin Kulasekararaj , MD, PhD, MPH
    King's College Hospital
    London,  United Kingdom

    Esther Natalie Oliva , MD
    Grande Ospedale Metropolitano Bianchi Melacrino Morelli
    Reggio Calabria,  Italy

    Kristen Marie Pettit
    C.S. Mott Children's Hospital
    Ann Arbor,  MI

    Abhay Singh , MD, MPH
    Cleveland Clinic
    Cleveland,  OH

    Kristin Bower , Cleveland Clinic
    Email: [email protected]

    Registration for In-Person Program

    Applying the Latest Evidence and NCCN Guideline Recommendations in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    This program is supported by Supported by educational grants from AstraZeneca, BeiGene, and Lilly. Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC.


    7:00 a.m. - 10:00 a.m. Pacific time
    Marriott Marquis San Diego Marina
    Pacific Ballroom Salons 21-22

    This NCCN-developed satellite symposium presents a great opportunity for healthcare professionals to interact with experts to be fully informed on the latest treatment advances in chronic lymphocytic leukemia (CLL). During the live event, the faculty will give an overview of recent clinical advances impacting today’s clinic along with emerging therapeutics in CLL. The symposium will also feature review of the latest updates to the NCCN Guidelines to help guide clinical application based on consensus recommendations and perspectives on emerging data. Data and guideline review will be complemented by panel discussions of various patient case scenarios with expert recommendations and supporting clinical data. NCCN Guidelines for Patients and PowerPoint slides outlining guideline recommendations will be made available to all in attendance. New developments on the near future horizon, including the utility of measurable residual disease and ongoing clinical trials of promising investigational approaches such as CAR T-cell therapy, will also be discussed. Text your questions directly to the panelists, and, throughout the program, the experts will take time to answer audience questions in order to provide their clinical approach, perspective, and interpretation of how the available clinical data should be applied to practice.

    Chair:

    Brian T. Hill , MD, PhD
    Cleveland Clinic
    Cleveland,  OH

    Speakers:

    Danielle M Brander , MD
    Duke Cancer Center
    Durham,  NC

    Deborah M. Stephens , DO
    University of Utah
    Salt Lake City,  UT

    Ishana Fleurant , Clinical Care Options, LLC
    Email: [email protected]

    Registration for In-Person Program
    Registration for Virtual Program

    BEYOND THE GUIDELINES: Clinical Investigator Perspectives on the Management of Patients with Follicular, Mantle Cell and Hodgkin Lymphoma (Part 1 of a 4-part CME-accredited Symposia Series)

    This program is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Genmab US Inc, Merck and Seagen Inc.


    7:00 a.m. - 10:00 a.m. Pacific time
    Omni San Diego
    Grand Ballroom, 4

    This CME program, offered for in-person and virtual attendees, will focus on the management of follicular, mantle cell and Hodgkin lymphoma. Six investigators will serve as faculty and the program will be moderated by Dr Neil Love, president of Research To Practice (RTP). Prior to the program, RTP will recruit 15 investigators, who, in addition to the participating faculty, will be asked to complete a case-based survey intended to illuminate their general practice patterns. In addition, RTP will recruit 3 “non-faculty member” investigators to participate in video recorded interviews with Dr Neil Love in which they will provide an explanation/justification for their responses to this same survey and share the scientific rationale.

    At the live event, for each module, Dr Love will present results from the survey, followed by video excerpts from the non-faculty member interviews. The faculty panelists will then be asked to register their level of agreement/disagreement with their colleagues’ answers and provide perspectives on their own responses. Each faculty will deliver a brief PPT presentation focused on reviewing recently published research data and ongoing clinical trials. Clinicians in attendance will have the opportunity to provide feedback on the same survey and present their own questions for discussion.

    Chair:

    Neil Love , MD
    Research To Practice
    Key Biscayne,  FL

    Speakers:

    Jeremy S. Abramson , MD
    Massachusetts General Hospital Cancer Center
    Boston,  MA

    Stephen M Ansell , MD, PhD
    Mayo Clinic
    Rochester,  MN

    Nancy L. Bartlett , MD
    Washington University School of Medicine
    Saint Louis,  MO

    Jonathon B. Cohen , MD,MS
    Winship Cancer Institute, Emory University
    Atlanta,  GA

    Jonathan W. Friedberg , MD, MMSc
    University of Rochester
    Rochester,  NY

    Brad S. Kahl , MD
    Washington University School of Medicine in St. Louis
    Saint Louis,  MO

    Sylvia Eriksen , Research To Practice
    Email: [email protected]

    Registration for In-Person Program
    Registration for Virtual Program

    Exploring Unmarked Territory in MDS: Taking Command and Enhancing Care with Team-Based Diagnosis and Treatment for Lower- and Higher-Risk Disease

    This program is supported by Bristol Myers Squibb, Geron Corporation, Karyopharm Therapeutics and Novartis Pharmaceuticals


    7:00 a.m. - 10:00 a.m. Pacific time
    San Diego Convention Center
    Ballroom 20CD

    This CME/MOC activity is provided by Penn State College of Medicine and developed with our educational partner, PVI, PeerView Institute for Medical Education.

    This activity is supported through educational grants from Astex Pharmaceuticals, Inc., Bristol Myers Squibb, Geron, Karyopharm Therapeutics, and Novartis Pharmaceuticals Corporation.

    The baseline assessment and subsequent management of myelodysplastic syndromes (MDS) is increasingly personalized to address the unique biology of this disorder and the well-recognized unmet medical needs of patients. PeerView’s unique Seminars & Tumor Board live event will explore this new therapeutic territory by pairing compelling case scenarios with collaborative real-world tumor board decision-making and, in doing so, provide expert guidance on the practice-changing evidence driving precision medicine in LR- and HR-MDS. Throughout, expert faculty will offer insights on 1) team-based methods for patient assessment, diagnosis, and prognostic assessment; 2) the challenges of characterizing and designing treatment plans for LR- and HR-MDS; 3) updated evidence supporting the use of innovative therapies for the 1L management of MDS anemia, ESA-refractory patients, and individuals presenting with high-risk mutations or cytogenetics (including TP53 mutations); and 4) practical strategies for effective delivery of care.

    Speakers:

    Rory M. Shallis , MD
    Section of Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center
    Killingworth,  CT

    Aditi Shastri , MD
    Albert Einstein College of Medicine
    Bronx,  NY

    Leigh Anne Bongiovanni , PVI, PeerView Institute for Medical Education
    Email: [email protected]

    Registration for In-Person Program
    Registration for Virtual Program

    Medical Crossfire®:Novel BTKi Strategies Transforming Aggressive and Indolent B-Cell Malignancies

    This program is supported by Lilly, Merck and Co., Inc., Pharmacyclics


    7:00 a.m. - 10:00 a.m. Pacific time
    San Diego Convention Center
    Room 6B

    The rapid pace and sheer volume of basic science and therapeutic developments that continue to emerge in the field of BTK inhibitors creates practice and/or educational gaps, particularly for hematology-oncologists and oncology nurses who strive to deliver the best possible care to patients. This Medical Crossfire® will provide an ideal format for the lymphoma care team to participate in an open exchange of ideas and viewpoints fostered by a case-based agenda allowing them to review patient scenarios, reflect on how they might handle particular cases, integrate relevant evidence into real-world practice, and compare their patient care approaches with those of experts and peers. Faculty leading discussion of common clinical scenarios and solutions will discuss methods to best integrate the latest therapies into B-cell lymphoma treatment paradigms, address barriers to optimized integration of these novel agents, as well provide best practices for the management of adverse events.

    Chair:

    Ian W. Flinn , MD, PhD
    Sarah Cannon Research Institute and Tennessee Oncology
    Nashville,  TN

    Speakers:

    Catherine C. Coombs , MD
    University of California Irvine
    Irvine,  CA

    Paolo Strati , MD
    The University of Texas MD Anderson Cancer Center
    Houston,  TX

    Kelly Donald , Physicians Education Resources, LLC
    Email: [email protected]

    Registration for In-Person Program
    Registration for Virtual Program

    Myelodysplastic Syndromes 2023: What’s New?

    This program is supported by MDS Foundation, Inc.


    7:00 a.m. - 10:00 a.m. Pacific time
    Marriott Marquis San Diego Marina
    San Diego Ballroom AB

    The 2023 Symposium will focus on recent advances in the diagnosis, classification and management of patients with myelodysplastic syndromes (MDS) and will be presented via lecture, debate and patient discussions. The program combines recent data, application of new tools and evidence on current practice with information that might be applied in the future.

    Chairs:

    Moshe Mittelman , MD
    Tel Aviv Sourasky Medical Center
    Tel Aviv,  Israel

    Rena Buckstein , MD, FRCPC
    Sunnybrook Health Sciences Centre, University of Toronto
    Toronto,  ON, Canada

    Speakers:

    Mario Cazzola , MD
    University of Pavia
    Pavia,  Italy

    Matteo Giovanni Della Porta , MD
    Cancer Center IRCCS Humanitas Research Hospital
    Milan,  Italy

    Guillermo Garcia-Manero , MD
    University of Texas MD Anderson Cancer Center
    Houston,  TX

    Aristoteles Giagounidis
    Marienhospital Düsseldorf
    Düsseldorf,  Germany

    Christopher James Gibson , MD
    Dana Farber Cancer Institute
    Boston,  MA

    Aziz Nazha , MD
    Cleveland Clinic
    Cleveland,  OH

    Uwe Platzbecker , MD
    Leipzig University Hospital
    Leipzig,  Germany

    Michael R. Savona , MD
    Vanderbilt University Medical Center
    Nashville,  TN

    Lea Harrison , MDS Foundation, Inc.
    Email: [email protected]

    Registration for In-Person Program

    Overcoming Racial Disparities in Multiple Myeloma Outcomes and Clinical Trials: How We are Moving Care Forward Today

    This program is supported by Regeneron Pharmaceuticals, Inc., Sanofi, and Takeda Pharmaceuticals U.S.A., Inc.


    7:00 a.m. - 10:00 a.m. Pacific time
    San Diego Convention Center
    Room 6A

    This agenda format designed to bring together faculty together to have open conversations about the pressing issue of healthcare inequities seen in practice. This peer-to-peer exchange will foster and open and honest discussion on inequities and potential interventions that can be implemented to improve care for all patients with multiple myeloma.

    Chair:

    Irene M. Ghobrial , MD
    Dana-Farber Cancer Institute
    Boston,  MA

    Speaker:

    Craig Emmitt Cole , MD
    Michigan State University
    East Lansing,  MI

    Kelly Donald , Physicians' Education Resource, LLC
    Email: [email protected]

    Registration for In-Person Program

    Raising the BCMA Standard in Multiple Myeloma: Strategies for Enhanced Care With Potent CAR-T and Bispecific Options

    This program is supported by Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, and Regeneron Pharmaceuticals, Inc.


    7:00 a.m. - 10:00 a.m. Pacific time
    Marriott Marquis San Diego Marina
    Pacific Ballroom Salons 15-17

    This CME/MOC/AAPA activity is provided by PVI, PeerView Institute for Medical Education, and developed with our educational partner HealthTree Foundation for Multiple Myeloma.

    This activity is supported by independent medical education grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, and Regeneron Pharmaceuticals, Inc.

    A new therapeutic standard has been raised in multiple myeloma (MM). In the wake of successes with CD38 antibody platforms, it became clear that as patients were increasingly treated with a greater number of active agents, strategies with unique mechanisms of action were required for patients exposed to multiple lines of modern therapy. Enter the BCMA options, including antibody-drug conjugates, bispecific antibodies, and cellular therapy.

    This symposium will take the story from there and offer expert-led, case-centered discussion on the major themes of treatment selection, sequencing across lines of therapy, and unique AE management that have emerged as new BCMA standards enter the clinic. Our experts will close each scientific segment by sharing resources from the HealthTree Foundation for Multiple Myeloma to support the real-world application of anti-BCMA platforms across the continuum of myeloma patient care. Join the experts in raising new standards of care for your patients with MM!

    Chair:

    Nikhil C. Munshi , MD
    Jerome Lipper Multiple Myeloma Center, Harvard Medical School
    Boston,  MA

    Speakers:

    Mohamad Mohty , MD,PhD
    Saint-Antoine Hospital, Sorbonne University
    Paris,  France

    Krina K. Patel , MD, Msc
    The University of Texas MD Anderson Cancer Center
    Houston,  TX

    Leigh Anne Bongiovanni , PVI, PeerView Institute for Medical Education
    Email: [email protected]

    Registration for In-Person Program
    Registration for Virtual Program

  • 2

    Early Afternoon Symposia

    11:00 a.m. - 2:00 p.m.
    Pacific time

    A Master Class in Personalized Myelofibrosis Care: Applying New Evidence and Novel Therapeutic Strategies to Improve Outcomes

    This program is supported by Educational grants from CTI Biopharma; Geron Corporation; GSK; and Karyopharm Therapeutics. Provided by Clinical Care Options, LLC.


    11:00 a.m. - 2:00 p.m. Pacific time
    Marriott Marquis San Diego Marina
    San Diego Ballroom AB

    During this symposium experts will review the latest data and provide practical insights on the diagnosis, risk stratification, and management of myelofibrosis (MF). As appropriate, each topic of the symposium will include a case review, didactic presentation, and interactive panel and audience engagement with opportunity for those in attendance to text questions and challenging case scenarios to the panelists. In this Master Class symposium participants can expect to interact with the experts as well as colleagues seated at your table to discuss data, guidelines, and disease factors that impact therapeutic decisions and then debate treatment recommendations for cases presented during the program. Discussion topics include: Partnering With Patients to Improve Outcomes and Quality of Life; Selecting Initial Treatment for Patients With Myelofibrosis; Recognizing Patterns of Suboptimal Response to Firstline MF Treatment; Beyond the First Line: Disease Progression or Intolerance to Initial Therapy; A Look to the Future: What’s on the Horizon in MF Treatment?

    Speakers:

    Jean-Jacques Kiladjian , MD,PhD
    Hopital Saint-Louis
    Paris,  France

    Abdulraheem Yacoub , MD
    The University of Kansas
    Leawood,  KS

    Ishana Fleurant , Clinical Care Options, LLC
    Email: [email protected]

    Registration for In-Person Program
    Registration for Virtual Program

    An MCL Quiz Game: Experts Review New and Emerging Therapies to Optimize Clinical Outcomes

    This program is supported by An educational grant from AstraZeneca. Provided by Clinical Care Options, LLC.


    11:00 a.m. - 2:00 p.m. Pacific time
    Marriott Marquis San Diego Marina
    Pacific Ballroom Salons 21-22

    The treatment of mantle cell lymphoma (MCL) is evolving. Join us for this innovative live satellite symposium that will feature a review and discussion of key clinical trial data with renowned clinical experts providing their perspectives focused specifically on BTK inhibitor-based therapy. In addition, enjoy a little friendly competition during the symposium as you will be challenged with a series of patient cases and polling questions presented as part of a Team Trivia style quiz game. Additionally, attendees will have ample ability to directly interact with the expert panel and contribute to the content of the program via submission of questions. Critical insights on the similarities and differences among multiple different BTK inhibitors will help prepare attendees to safely and effectively use these agents in their practice. Discussion and case topics will include: 1) Recent updates to the treatment landscape in MCL; 2) Mechanisms, pharmacokinetics, pharmacodynamics, and efficacy of currently available BTK inhibitors; 3) The evolving role of BTK inhibitors in treatment-naïve MCL; 4) The management of relapsed/refractory disease considering resistance or intolerance to prior therapy; 5) Practical discussions with multiple expert perspectives on the implementation of new data and current clinical challenges.

    Chair:

    John P. Leonard
    Weill Cornell Medicine
    New York,  NY

    Speakers:

    Ann LaCasce , MD
    Dana Farber Cancer Institute
    Boston,  MA

    Matthew A Lunning , DO, FACP
    Pathology and Microbiology University of Nebraska
    Omaha,  NE

    Ishana Fleurant , Clinical Care Options, LLC
    Email: [email protected]

    Registration for In-Person Program
    Registration for Virtual Program

    BEYOND THE GUIDELINES: Clinical Investigator Perspectives on the Management of Patients with Diffuse Large B-Cell Lymphoma (Part 2 of a 4-part CME-accredited Symposia Series)

    This program is supported by educational grants from ADC Therapeutics, Genentech, a member of the Roche Group, Incyte Corporation, Kite, A Gilead Company and Regeneron Pharmaceuticals Inc


    11:00 a.m. - 2:00 p.m. Pacific time
    Omni San Diego
    Grand Ballroom, 4

    This CME-accredited program, offered for in-persom and virtual attendees, will focus on the management of patients with Diffuse Large B-Cell Lymphoma. Four investigators will serve as faculty and the program will be moderated by Dr Neil Love, president of Research To Practice (RTP). Prior to the program, RTP will recruit 15 clinical investigators, who, in addition to the participating faculty, will be asked to complete a case-based survey intended to illuminate their general practice patterns.

    At the live event, for each module, Dr Love will present results from the case-based survey and the faculty members on stage will then be asked to register their level of agreement/disagreement with their colleagues’ answers and provide perspectives on their own responses. Each faculty member will also deliver a brief PPT presentation focused on reviewing recently published research data and ongoing clinical trials. Clinicians in attendance (both in person and virtually) will have the opportunity to provide feedback on the same survey and present their own questions for discussion with the faculty.

    Chair:

    Neil Love , MD
    Research To Practice
    Key Biscayne,  FL

    Speakers:

    Michael Dickinson , MBBS, D. Med Sci, FRACP, FRCPA
    Peter MacCallum Cancer Centre and The Royal Melbourne Hospital
    Melbourne,  VIC, Australia

    Grzegorz S. Nowakowski , MD
    Mayo Clinic
    Rochester,  MN

    Gilles Salles , MD, PhD
    Memorial Sloan Kettering Cancer Center
    New York,  NY

    Laurie H. Sehn , MD, MPH
    BC Cancer Centre for Lymphoid Cancer and The University of British Columbia
    Vancouver, BC,  Canada

    Jason Westin , MD
    The University of Texas M D Anderson Cancer Center
    Houston,  TX

    Sylvia Eriksen , Research To Practice
    Email: [email protected]

    Registration for In-Person Program
    Registration for Virtual Program

    CAR T-Cell Therapies in Relapsed/Refractory Multiple Myeloma: Evaluating the Evidence for Optimal Integration

    This program is supported by educational grants from Bristol Myers Squibb and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.


    11:00 a.m. - 2:00 p.m. Pacific time
    San Diego Convention Center
    Room 30 A-E

    The evolution of CAR-T therapies – where do we stand now with this revolutionary treatment approach?

    Join our faculty experts for this 1-hour accredited event about the current role of CAR T-cell therapies in management of patients with relapsed/refractory multiple myeloma (RRMM). Dr. Ajai Chari and Dr. Sikander Ailawadhi will discuss and debate practical challenges such as: Is prior treatment sequencing a significant factor in patient response to CAR T-cell therapy? Should all eligible patients with RRMM receive CAR T-cell therapy, or is fitness/frailty a concern? How can we prevent, identify, and manage adverse events? When is treatment discontinuation the best choice? What administration and cost issues need to be considered? And more...

    Bring your hard-hitting questions - attendees can challenge the faculty through our interactive Q&A, and the faculty will challenge you back with a series of interactive, case scenarios.

    Speakers:

    Sikander Ailawadhi , MD
    Mayo Clinic
    Jacksonville,  FL

    Ajai Chari , MD
    Division of Hematology/Oncology, Mount Sinai School of Medicine
    New York,  NY

    Caitlan Bose , Answers in CME
    Email: [email protected]

    Registration for In-Person Program

    Controlling and Conquering CLL: Guidance on Modern Targeted Options, Innovative Combinations, and Sequential Management

    This program is supported by AbbVie; AstraZeneca; Lilly; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.


    11:00 a.m. - 2:00 p.m. Pacific time
    San Diego Convention Center
    Ballroom 20CD

    This CME/MOC activity is provided by Penn State College of Medicine and developed with our educational partners, PVI, PeerView Institute for Medical Education, and CLL Society.

    This activity is supported by independent educational grants from AbbVie; AstraZeneca; Lilly; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

    Choosing well and wisely when deciding on the management of CLL has never been more important. Modern therapeutic platforms based on BTKi and BCL2i have demonstrated efficacy against higher-risk disease, in the relapsed/refractory setting, and as combination or sequential strategies, and newer chemosparing combinations and non-covalent BTKi are poised to overcome challenges in CLL. How will these developments be used going forward, and is long-lasting disease suppression an achievable goal?

    Find out by joining an expert panel convened to take on the challenges of CLL and who will share real-world cases to provide guidance on how to implement modern treatment protocols and cover topics such as: choosing between continuous or fixed-duration first-line regimens; BTKi/BCL2i combination platforms; and sequential therapy with non-covalent BTKi options. In partnership with the CLL Society, these important topics will be framed by patient perspectives, including commentary from CLL survivors.

    Chair:

    Prof. John G. Gribben , MD, DSc
    Barts Cancer Institute, Barts and The London School of Medicine, Queen Mary, University of London
    London,  United Kingdom

    Speakers:

    John N. Allan , MD
    Weill Cornell Medicine
    New York,  NY

    Nicole Lamanna , MD
    Herbert Irving Comprehensive Cancer Center, New York-Presbyterian/Columbia University Medical Center
    New York,  NY

    Meghan C. Thompson , MD
    Memorial Sloan Kettering Cancer Center
    New York,  NY

    Leigh Anne Bongiovanni , PVI, PeerView Institute for Medical Education
    Email: [email protected]

    Registration for In-Person Program
    Registration for Virtual Program

    Experts Address the Hottest Topics in AML: Considerations on FLT3, IDH1/2, TP53, Maintenance, Novel Combinations and Beyond!

    This program is supported by Rigel Pharmaceuticals, Inc., Syndax Pharmaceuticals, Inc., Jazz Pharmaceuticals, Inc., Gilead Sciences, Inc., Daiichi Sankyo, Inc.; Curis, Inc.


    11:00 a.m. - 2:00 p.m. Pacific time
    San Diego Convention Center
    Room 6A

    The live activity will feature a series of didactic presentations coupled with case-based panel discussions and question-and-answer sessions from the audience. Using a blended instructional model of didactic presentations and interactive panel discussions is intended is to improve medical practices and patient care through evidence-based presentations, discussion, and authoritative peer-exchange on important clinical issues. The satellite program will bring together 5 clinical experts to highlight novel agents in the management of AML, including the latest clinical data and application of targeted therapies, combination, maintenance therapy, and beyond.

    Chair:

    Naval Daver , MD
    The University of Texas MD Anderson Cancer Center
    Houston,  TX

    Speakers:

    Courtney D. DiNardo , MD, MSc
    The University of Texas MD Anderson Cancer Center
    Houston,  TX

    Gail J. Roboz , MD
    Weill Cornell Medicine and The New York Presbyterian Hospital
    New York,  NY

    Eytan M. Stein , MD
    Memorial Sloan Kettering Cancer Center
    New York,  NY

    Kelly Donald , Physicians' Education Resource, LLC
    Email: [email protected]

    Registration for In-Person Program
    Registration for Virtual Program

    Hitting the Mark? Targeted Antibody-Based Therapy for Diffuse Large B-cell Lymphoma

    This program is supported by Genmab, US Inc. and ADC Therapeutics


    11:00 a.m. - 2:00 p.m. Pacific time
    San Diego Convention Center
    Room 6DE

    Join expert DLBCL faculty as they take a deep dive into the latest clinical evidence and practical considerations for evidence-based integration of antibody-based therapies into treatment plans for DLBCL. Informed by real-world data from a recent quality improvement initiative, this satellite symposium will support DLBCL care teams in examining the latest evidence, differentiating new and emerging antibody-based therapies for DLBCL, and addressing barriers to novel therapy adoption. The topics for discussion by the expert faculty panel will be supported by clinical cases and enhanced by interactive polling questions and live questions submitted by attendees throughout the presentation. Additionally, a whiteboard animation video will be featured during the presentation, designed to illustrate the unique mechanisms of action of new and emerging novel, targeted antibody-based therapies for DLBCL. Altogether, this satellite symposium will harness real-world experiences providing DLBCL care to deepen the impact of the education on new and emerging antibody-based therapy, utilizing a case-based approach to provide a basis for discussion and strategy to enhance patient-centered care.

    Chair:

    Krish Patel , MD
    Swedish Cancer Institute
    Seattle,  WA

    Speakers:

    Douglas Burgoyne , PharmD, FAMCP
    University of Utah
    Salt Lake City,  UT

    Krish Patel , MD
    Swedish Cancer Institute
    Seattle,  WA

    Peter A. Riedell , MD
    University of Chicago
    Chicago,  IL

    Jill Friedman , PRIME Education, LLC
    Email: [email protected]

    Medical Crossfire: how Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

    This program is supported by American Regent, Inc.


    11:00 a.m. - 2:00 p.m. Pacific time
    Marriott Marquis San Diego Marina
    Pacific Ballroom Salons 24-26

    There is an the unmet need for educational activities designed to close the gap in knowledge for physicians who treat or manage patients with cancer-related anemia. This program is centered around improving medical practices and patient care for those who are diagnosed with cancer-related iron deficiency anemia and will feature a mix of didactic and discussion sessions. This satellite will aim to provide an overview of pathophysiologic mechanisms and prevalence of cancer-related iron deficiency anemia, current applications of iron supplementation including a breakdown of oral versus IV iron, case discussions, and what oncologists/hematologists can do to address challenges with diagnosis and management of patients.

    Chair:

    George M. Rodgers , MD, PhD
    Univ. of Utah Medical Center
    Salt Lake City,  UT

    Speaker:

    Patricia A. Locantore-Ford , MD
    Pennsylvania Hospital
    Philadelphia,  PA

    Jim Palatine , Physicians Education Resource
    Email: [email protected]

    Registration for In-Person Program
    Registration for Virtual Program

    Medical Crossfire®:Bridging Expert Guidance and Evidence-Based Recommendations in the Treatment of AYA and Adult ALL

    This program is supported by Amgen, Inc., Takeda Oncology


    11:00 a.m. - 2:00 p.m. Pacific time
    Marriott Marquis San Diego Marina
    Marriott Grand Ballroom 11-13

    This Medical Crossfire® will provide an ideal format for the ALL care team to participate in an open exchange of ideas and viewpoints fostered by a case-based agenda allowing them to review patient scenarios, reflect on how they might handle particular cases, integrate relevant evidence into real-world practice, and compare their patient care approaches with those of experts and peers. Faculty leading discussion of common clinical scenarios and solutions will discuss methods to best integrate the latest therapies into ALL treatment paradigms, address barriers to optimized integration of these novel agents, as well provide best practices for the management of adverse events.

    Chair:

    Elias Jabbour , MD
    University of Texas M.D. Anderson Cancer Ctr.
    Houston,  TX

    Speakers:

    Lia Gore , MD
    University of Colorado Cancer Center
    Aurora,  CO

    Hagop M. Kantarjian , MD
    University of Texas MD Anderson Cancer Center
    Houston,  TX

    Aaron C. Logan , MD, PhD
    University of California San Francisco
    San Francisco,  CA

    Claire Roddie , MD, PhD
    University College London
    LONDON,  GBR

    Kelly Donald , Physicians' Education Resource, LLC
    Email: [email protected]

    Registration for In-Person Program
    Registration for Virtual Program

    More Than a Disease: Exploring the Patient Journey for Chronic Immune Thrombocytopenia

    This program is supported by an independent educational grant from Argenx US, Inc., Sanofi, and Novartis Oncology.


    11:00 a.m. - 2:00 p.m. Pacific time
    Marriott Marquis San Diego Marina
    Marriott Grand Ballroom 2-4

    This 90-minute, live, interactive symposium will feature expert faculty as well as a patient with ITP to underscore the value of the patient voice throughout the management of ITP. Expert faculty will provide a detailed overview of the mechanisms of ITP and its key clinical features, present diagnostic and treatment challenges and how to overcome them, as well as discuss data on current and emerging therapies to inform the best clinical choices for patients. A big emphasis will be placed on the importance of shared-decision making with the interdisciplinary team for improving outcomes for their patients. Interactive polling questions and a Q&A session will allow for audience engagement and added learning.

    Chair:

    Spero Cataland , MD
    Ohio State University Comprehensive Cancer Center
    Columbus,  OH

    Speakers:

    Srikanth Nagalla , MBBS
    Miami Cancer Institute
    Miami,  FL

    Marie Scully , MD
    University College London
    London,  ENG, United Kingdom

    Harmony Washington , Medscape Oncology
    Email: [email protected]

    Registration for In-Person Program
    Registration for Virtual Program

    Multiple Myeloma: Clinical Challenges for the Community Clinician

    This program is supported by Bristol Myers Squibb, Janssen, Sanofi, Karyopharm, and Legend


    11:00 a.m. - 2:00 p.m. Pacific time
    Marriott Marquis San Diego Marina
    Marriott Grand Ballroom 5-6

    This 90-minute interactive symposium will feature a panel of experts evaluating the intricacies of care for patients with multiple myeloma through a series of challenging clinical cases. They will provide expert guidance and real-world perspectives related to optimizing outcomes at each phase of the treatment journey. Attendees can participate in interactive case challenges and engage directly with the expert panel in a closing Q&A session.

    Chair:

    C. Ola Landgren , MD, PhD
    Sylvester Comprehensive Cancer Center, University of Miami
    Miami,  FL

    Speakers:

    Luciano Costa , MD,PhD
    The University of Alabama at Birmingham
    Vestavia,  AL

    Nisha S. Joseph , MD
    Winship Cancer Institute of Emory University
    Atlanta, 

    Harmony Washington , Medscape Oncology
    Email: [email protected]

    Registration for In-Person Program
    Registration for Virtual Program

    Optimizing Myelofibrosis Management With Current and Emerging Therapies

    This program is supported by AbbVie, Bristol -Myers Squibb Company, GSK, and Karyopharm Therapeutics


    11:00 a.m. - 2:00 p.m. Pacific time
    Marriott Marquis San Diego Marina
    Marriott Grand Ballroom 8-9

    This 90-minute symposium will present a comprehensive review of the recent updates related to current and emerging therapies in MF. Featuring a lively and engaging format resembling a talk show, 3 expert faculty in MF will discuss the evolving MF treatment paradigm. Discussion will review the current treatment landscape, emerging therapies, and practical management strategies to optimize patient outcomes. The program will also contain a “Query the Experts”-style Q&A, in which each panelist takes turns presenting a challenging case scenario to the others to elicit discussion and compare approaches, with accompanying audience polling questions to stimulate discussion.

    Chair:

    Prithviraj Bose , MD
    MD Anderson Cancer Center
    Houston,  TX

    Speakers:

    Stephen T. Oh , MD,PhD
    Washington University School of Medicine
    Saint Louis,  MO

    Nikolai A. Podoltsev , MD, PhD
    Yale School of Medicine
    New Haven,  CT

    Harmony Washington , Medscape Oncology
    Email: [email protected]

    Registration for In-Person Program
    Registration for Virtual Program

    Reimagining Outcomes in Hemophilia: Improving Efficacy and Reducing Treatment Burden with High-Sustained Factor and Non-Factor Replacement Therapies

    This program is supported by Sanofi


    11:00 a.m. - 2:00 p.m. Pacific time
    Marriott Marquis San Diego Marina
    Pacific Ballroom Salons 18-19

    This session will explore the latest understanding of hemostasis as it relates to the pathology of hemophilia, highlight the mechanism of action, using clinical animations, of new and emerging hemophilia treatments, discuss the efficacy and safety of novel therapies, and utilize clinical case scenarios to explore practical implications of newly approved and upcoming therapies.

    Chair:

    Guy Young , MD
    Children's Hospital Los Angeles
    Los Angeles,  CA

    Speakers:

    Glaivy Batsuli , MD
    Stanford University
    Stanford,  CA

    Cindy A. Leissinger , MD
    Tulane University School of Medicine
    New Orleans,  LA

    Cathy Zehr , Catalyst Medical Education
    Email: [email protected]

    Registration for In-Person Program
    Registration for Virtual Program

    Show Me the Data™: How Do We Navigate the Latest Evidence on Novel Therapies, Combinations, and Clinical Trials Across MPN Care in the Context of Current Treatment Algorithms?

    This program is supported by Geron Corporation, Incyte Corporation, Protagonist Therapeutics, PharmaEssentia USA


    11:00 a.m. - 2:00 p.m. Pacific time
    San Diego Convention Center
    Room 6B

    The live portion of this curriculum will be presented as a 2.5-hour Friday Satellite Symposium (FSS) held prior to the 2023 ASH Annual Meeting. This agenda has been developed in an interactive Show Me the Data format where experts will lead case-based panel discussions regarding the latest clinical advances in treating and managing patients with myeloproliferative neoplasms (MPNs) with novel treatment approaches and emerging treatment strategies in the context of current paradigms.

    After each “decision point,” the chair will challenge the faculty member to Show Me the Data! that backs up their decision-making. Faculty will be probed on how emerging strategies under investigation may impact future treatment decision-making. ARS will be utilized throughout to identify learners current knowledge and competence levels at the beginning and conclusion of each case scenario.

    To further enhance the integration of recent data into practice, the program will feature an interactive question-and-answer session between the faculty and attendees to emphasize areas of educational need, highlight areas of debate, and illustrate the application of new data in defined clinical situations.

    Chair:

    Andrew T. Kuykendall , MD
    Moffitt Cancer Center
    Tampa,  FL

    Speakers:

    Gabriela S. Hobbs , MD
    Massachusetts General Hospital
    Boston,  MA

    Barbara Mora , MD
    Division of Hematology, Ospedale ASST Sette Laghi, University of Insubria
    Varese,  Italy

    Naveen Pemmaraju , MD
    MD Anderson Cancer Cneter
    Houston,  TX

    Kelly Donald , Physicians' Education Resource, LLC
    Email: [email protected]

    Registration for In-Person Program
    Registration for Virtual Program

    Untangling Amyloidosis 2023: Diagnosis, Prognosis, Selection of Individualized Therapy, and Management of Difficult Clinical Complications

    This program is supported by Prothena, Amyloidosis Foundation Amyloidosis Support Group


    11:00 a.m. - 2:00 p.m. Pacific time
    San Diego Convention Center
    Ballroom 20AB

    The Karmanos Cancer Institute, in collaboration with the Amyloidosis Support Groups, Inc., is developing a CME symposium to be conducted on Friday, December 8th, 2023, preceding the annual American Society of Hematology (ASH) meeting. It will consist of evidence-based presentations focused on the diagnosis, pathophysiology, prognosis, and treatment of systemic amyloidosis. The complexities of making a timely, accurate diagnosis of amyloidosis will be discussed, with emphasis placed on distinguishing AL amyloidosis from the other most common type of amyloidosis, ATTR. Selection of appropriate initial anti-plasma cell therapy of AL amyloidosis will be highlighted. Investigational light chain and fibril-directed agents will be discussed, as will novel potential therapeutic strategies mirroring approved ATTR therapies. Finally, we will review the pathophysiology of bleeding and clotting complications in AL amyloidosis, providing attendees practical clinical management guidance. We intend to live-stream the presentations to expand the audience beyond those attending in-person. The program is intended to be interactive and the live audience will be asked to provide opinions and answers to questions intermittently throughout the program via an audience response system (ARS). A panel discussion after the speakers' presentations will provide an opportunity to address questions from the live audience.

    Chair:

    Jeffrey A. Zonder
    Karmanos Cancer Institute
    Detroit,  MI

    Speakers:

    Giada Bianchi , MD
    Brigham and Women's Hospital
    Boston,  MA

    Simon Gibbs , FRACP, FRCPA, MBBS
    Eastern Health
    Box Hill,  Australia

    Eli Muchtar , MD
    Mayo Clinic
    Rochester,  MN

    Laura Obici , MD
    Fondazione IRCCS Policlinico San Matteo
    Pavia,  ITA

    Christiane A. Houde , Karmanos Cancer Institute
    Email: [email protected]

    Registration for In-Person Program
    Registration for Virtual Program

  • 3

    Late Afternoon Symposia

    3:00 p.m. - 6:00 p.m.
    Pacific time

    A Rare Day in the Community Hematology Clinic: Interesting Cases in Classical Hematology

    This program is supported by Agios, Novartis Oncology


    3:00 p.m. - 6:00 p.m. Pacific time
    Marriott Marquis San Diego Marina
    Marriott Grand Ballroom 11-13

    Sickle cell disease (SCD) is the world’s most common genetic disease, affecting more than 3 million people worldwide. Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired form of intravascular hemolysis with a worldwide incidence of five to six cases per million people and a prevalence of 16 cases per million people. In this live symposium, 2 experts in the field of SCD and PNH will delve into the identification, diagnosis, treatment nuances, and overall management of these 2 classic hematologic malignancies using case studies as a practical guide. Additionally, our panel will discuss the implications of health inequities and how to address more accessible, equitable, cost-effective, and person-centered care for patients affected with PNH and SCD.

    Chair:

    Morag Griffin , FRCPath,MRCP
    St James's University Hospital
    Leeds,  United Kingdom

    Speaker:

    Michael R. DeBaun , MD, MPH
    Vanderbilt University Medical Center
    Nashville,  TN

    Harmony Washington , Medscape Oncology
    Email: [email protected]

    Registration for In-Person Program
    Registration for Virtual Program

    Achieving “Next-Level” Care in AML: Conversations on Targeted Platforms, Emerging Immunotherapies, and Implications for Precision Medicine

    This program is supported by AbbVie, Actinium Pharmaceuticals, Astellas, Kura Oncology, Inc., and Syndax.


    3:00 p.m. - 6:00 p.m. Pacific time
    Marriott Marquis San Diego Marina
    Pacific Ballroom Salons 15-17

    This CME activity is provided by Penn State College of Medicine and developed with our educational partners, PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Myeloid Leukemia.

    This activity is supported by independent educational grants from AbbVie, Actinium Pharmaceuticals, Astellas, Kura Oncology, Inc., and Syndax.

    The modern management of acute myeloid leukemia (AML) has changed dramatically in recent years as innovative therapeutics, including FLT3, IDH, and BCL2 inhibitors; novel radioimmunoconjugate approaches; and newer epigenetic and targeted therapeutics (eg, menin inhibitors), have overturned the largely cytarabine-based chemotherapy standard of patient care. Strategic treatment planning is now more important than ever to ensure the safe delivery of different therapeutic drug classes.

    To explore this “next level” of AML management, PeerView’s experts will use case-based Clinical Consult debates to illustrate how varying baseline patient features can alter treatment decisions and discuss strategies to leverage the fruits of new science to improve patient care. Each discussion will be supported by mini lectures covering current science and modern clinical decision-making strategies in a diversity of AML settings and patient presentations. Join us to achieve “next-level” care for your patients with AML!

    Chair:

    Sergio A. Giralt , MD, FACP
    Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center
    New York,  NY

    Speakers:

    Pinkal Desai , MD, MPH
    Weill Cornell Medicine, The New York Presbyterian Hospital
    New York,  NY

    Ghayas C. Issa , MD
    The University of Texas MD Anderson Cancer Center
    Houston,  TX

    Tapan M. Kadia , MD
    The University of Texas MD Anderson Cancer Center
    Houston,  TX

    Selina M Luger , MD,FRCPC
    Perelman School of Medicine, Hospital of the University of Pennsylvania
    Philadelphia,  PA

    Leigh Anne Bongiovanni , PVI, PeerView Institute for Medical Education
    Email: [email protected]

    Registration for In-Person Program
    Registration for Virtual Program

    Advances in Autoimmune Hemolytic Anemia: Targeting the Complement Cascade in Cold Agglutinin Disease

    This program is supported by Sanofi. Provided by Clinical Care Options, LLC.


    3:00 p.m. - 6:00 p.m. Pacific time
    Marriott Marquis San Diego Marina
    San Diego Ballroom AB

    This interactive symposium will feature a unique learning opportunity to gain and update on the latest clinical advances in the care of patients with cold agglutinin disease (CAD). The symposium format will include presentations and case-based panel discussions with perspectives and treatment recommendations from multiple experts. In addition, the panel will address audience questions and practice challenges identified in the “Live Case and Question Submission”, which can be sent directly to the symposium faculty. You can expect to receive a review of cutting-edge clinical evidence along with a presentation of evolving treatment algorithms for CAD into 2024. Program topics will include an overview CAD and the associated pathophysiology, clinical presentation and diagnosis of CAD; current/evolving management algorithm for the patient with newly diagnosed CAD and the management of CAD-related anemia, fatigue, and hemoglobinuria; challenges and strategies to address quality of life in patients with CAD; plus novel treatments on the horizon and future directions.

    Chair:

    Catherine Broome , MD
    Georgetown University
    Washington,  DC

    Speakers:

    David Dingli , MD
    Mayo Clinic
    Rochester,  MN

    Deva Sharma , MD
    Vanderbilt University School of Medicine
    Nashville,  TN

    Ishana Fleurant , Clinical Care Options, LLC
    Email: [email protected]

    Registration for In-Person Program
    Registration for Virtual Program

    Advances in Precision Medicine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Care

    This program is supported by an educational grant from Genmab US, Inc. and AbbVie


    3:00 p.m. - 6:00 p.m. Pacific time
    San Diego Convention Center
    Room 30 A-E

    This activity is intended to educate clinicians regarding the use and integration of new and emerging BCMA-targeted therapies in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). In the “Care Team Forum,” an expert panel will present 3 series of didactic slides, followed by discussion that will include a patient with R/R DLBCL; they will share key aspects of their therapeutic journey. Polling questions will be interspersed throughout the symposium to assess improvements in knowledge and competence among attendees.

    Chair:

    Joshua Brody , MD
    Icahn School of Medicine at Mount Sinai
    New York,  NY

    Speakers:

    Lorenzo Falchi , MD
    Memorial Sloan Kettering Cancer Center
    New York,  NY

    Catherine Thieblemont , MD, PhD
    Université de Paris
    Paris,  France

    Erika Sinofsky , RMEI Medical Education, LLC
    Email: [email protected]

    Advancing cTTP Care Through Integration of the Latest Clinical Evidence

    This program is supported by This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. This activity is provided by PRIME Education. There is no fee to participate.


    3:00 p.m. - 6:00 p.m. Pacific time
    San Diego Convention Center
    Ballroom 20AB

    Join expert cTTP faculty as they take a deep dive into the latest clinical evidence and practical considerations for evidence-based integration of emerging treatment and management strategies for cTTP. Informed by real-world data from a recent hematology provider survey to uncover key gaps and barriers faced in the treatment and management of cTTP, this satellite symposium will support hematology care teams in examining and integrating the latest evidence on cTTP treatment and management into clinical practice. The topics for discussion by the expert faculty panel will be supported by clinical cases and enhanced by interactive polling questions and live questions submitted by attendees throughout the presentation. Additionally, a whiteboard animation video will be featured during the presentation, designed to illustrate the pathophysiology of cTTP and novel mechanisms of action of emerging cTTP treatments. Altogether, this satellite symposium will harness real-world experiences providing cTTP care to deepen the impact of the education on emerging evidence, utilizing a case-based approach to provide a basis for discussion and strategy to enhance patient-centered care.

    Speaker:

    Thomas L. Ortel , MD, PhD
    Duke University Medical Center
    Durham,  NC

    Eryn Litvinas , PRIME Education, LLC
    Email: [email protected]

    AL Amyloidosis: Advancements and Future Trends on Diagnosis and Individualized Treatment Approaches

    This program is supported by Educational grants from Alexion Pharmaceuticals; Janssen Biotech Inc., administered by Janssen Scientific Affairs, LLC; and Prothena. Provided by Clinical Care Options, LLC.


    3:00 p.m. - 6:00 p.m. Pacific time
    Marriott Marquis San Diego Marina
    Pacific Ballroom Salons 21-22

    This interactive symposium will feature presentations and case-based panel discussions with perspectives and treatment recommendations from experts. Participate in our unique "Live Case and Question Submission", forwarding your queries and real-life cases to our faculty for tailor-made insights. Experts will explore the current state of AL amyloidosis treatment, dissect breakthrough clinical evidence, and anticipate evolving strategies into 2024. Key topics include a deep dive into the biology, clinical presentation, and diagnostic approach for AL amyloidosis, a review of the latest treatment guidelines, insights into managing newly diagnosed and relapsed AL amyloidosis, future directions in treatment, and supportive management strategies for improving patients' quality of life. Enrich your understanding, challenge your clinical skills, and contribute to our insightful dialogue on AL amyloidosis in this dynamic, interactive symposium.

    Chair:

    Angela Dispenzieri , MD
    Mayo Clinic
    Rochester,  MN

    Speaker:

    Ashutosh D. Wechalekar , MBBS,DM,FRCP,FRCPath
    University College London Hospitals
    London,  United Kingdom

    Ishana Fleurant , Clinical Care Options, LLC
    Email: [email protected]

    Registration for In-Person Program
    Registration for Virtual Program

    Amplifying New and Emerging Clinical Evidence in the Treatment and Management of Myelodysplastic Syndrome

    This program is supported by Gilead Sciences, Inc.


    3:00 p.m. - 6:00 p.m. Pacific time
    San Diego Convention Center
    Room 6DE

    Join expert MDS faculty as they take a deep dive into the latest clinical evidence and applications for MDS treatment and management. Informed by provider surveys designed to assess knowledge and confidence gaps in MDS testing, risk assessment, and differentiating new and emerging therapies, as well as barriers to integrating the latest evidence into clinical practice, this satellite symposium will support MDS care teams in examining the latest evidence, differentiating new and emerging therapies for MDS, and addressing barriers to novel therapy adoption. The topics for discussion by the expert faculty panel will be supported by clinical cases and enhanced by interactive polling questions and live questions submitted by attendees throughout the presentation. Additionally, through partnership with the MDS Foundation, a patient vignette will be incorporated into the symposium highlighting disease burden and real-world experiences in care to deepen the impact of the education and provide a basis for discussion and strategy to enhance patient-centered care.

    Chair:

    Amer M. Zeidan , MBBS, MHS
    Yale University
    New Haven,  CT

    Speakers:

    Douglas Burgoyne , PharmD, FAMCP
    University of Utah
    Salt Lake City,  UT

    Rami S. Komrokji , MD
    Moffitt Cancer Center
    Tampa,  FL

    Eryn Litvinas , PRIME Education, LLC
    Email: [email protected]

    An Expert Guide to What’s New and What’s Next for Novel Targeted Therapies in Relapsed/Refractory Follicular Lymphoma

    This program is supported by Educational grants from Genentech, a member of the Roche Group; Genmab; Ipsen Biopharmaceuticals, Inc; and Regeneron Pharmaceuticals, Inc. Provided by Clinical Care Options, LLC.


    3:00 p.m. - 6:00 p.m. Pacific time
    Marriott Marquis San Diego Marina
    Pacific Ballroom Salons 18-19

    This dynamic symposium will combine engaging presentations and case-oriented panel discussions, showcasing expert opinions and treatment advice for relapsed/refractory (R/R) Follicular Lymphoma (FL). Directly engage with the expert panelists during the "Live Case and Question Submission" sessions during which you can present your questions and real-world cases to our experienced faculty for customized guidance. The symposium will navigate the current landscape of R/R FL treatment, unpack ground-breaking clinical research, and project future strategies into 2024. This experience promises to enrich your understanding of R/R FL, challenge your clinical acumen, and empower you to implement the latest knowledge in your practice. We invite you to contribute to this thought-provoking dialogue on R/R FL, shaping the discourse and contributing to the collective understanding of this critical area.

    Chair:

    Julie M. Vose , MD, MBA
    Univeristy of Nebraska Medical Center
    Omaha,  NE

    Speakers:

    Peter Martin , MD
    Weill Cornell Medical College
    New York,  NY

    Sonali M. Smith
    University of Chicago
    Chicago,  IL

    Ishana Fleurant , Clinical Care Options, LLC
    Email: [email protected]

    Registration for In-Person Program
    Registration for Virtual Program

    BEYOND THE GUIDELINES: Clinical Investigator Perspectives on the Management of Patients with Chronic Lymphocytic Leukemia (Part 3 of a 4-part CME-accredited Symposia Series)

    This program is supported by educational grants from AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb and Lilly


    3:00 p.m. - 6:00 p.m. Pacific time
    Omni San Diego
    Grand Ballroom, 4

    This CME-accredited program, offered for in-person and virtual attendees, will focus on the management of chronic lymphocytic leukemia (CLL). Five investigators will serve as faculty and the program will be moderated by Dr Neil Love, president of Research To Practice (RTP). Prior to the program, RTP will recruit 15 investigators, who, in addition to the participating faculty, will be asked to complete a case-based survey intended to illuminate their general practice patterns. In addition, RTP will recruit 3 “non-faculty member” investigators to participate in video recorded interviews with Dr Neil Love in which they will provide an explanation/justification for their responses to this same survey and share the scientific rationale.

    At the live event, for each module, Dr Love will present results from the survey, followed by video excerpts from the non-faculty member interviews. The faculty panel will be asked to register their level of agreement/disagreement with their colleagues’ answers and provide perspectives on their own responses. Each faculty member will also deliver a brief PPT presentation focused on reviewing recently published research data and ongoing clinical trials. Clinicians in attendance will have the opportunity to provide feedback on the same survey and present their own questions for discussion.

    Chair:

    Neil Love , MD
    Research To Practice
    Key Biscayne,  FL

    Speakers:

    Farrukh T. Awan , MD
    The University of Texas
    Dallas,  TX

    Matthew S Davids , MD, MMSc
    Dana-Farber Cancer Institute
    Boston,  MA

    Stephen J. Schuster , MD
    University of Pennsylvania
    Philadelphia,  PA

    William G. Wierda , MD, PhD
    MD Anderson Cancer Center
    Houston,  TX

    Jennifer A. Woyach , MD
    The Ohio State University Comprehensive Cancer Center
    Columbus,  OH

    Sylvia Eriksen , Research To Practice
    Email: [email protected]

    Registration for In-Person Program
    Registration for Virtual Program

    Case Challenges in Myelofibrosis for the Community Clinician

    This program is supported by CTI Biopharma Corp


    3:00 p.m. - 6:00 p.m. Pacific time
    Marriott Marquis San Diego Marina
    Marriott Grand Ballroom 5-6

    Three experts will engage in a case-based discussion of clinical data, real-world experience, and optimal management strategies for the treatment of higher-risk MF. Patient cases will be introduced and revisited throughout the program to illustrate how experts interpret and apply the latest clinical data to various case scenarios. Discussion will center around the importance of ongoing prognostic risk stratification and symptom assessment; considerations in treatment selection and sequencing, including optimizing dosage, assessing treatment resistance or intolerance, and determining when and how to switch therapies; prevention and mitigation of adverse events; and the role of allogeneic transplant and clinical trials. Learners will be prompted to share their thoughts throughout the program in audience polls and the faculty will conclude with an interactive Q&A session.

    Chair:

    Ruben A. Mesa , MD
    Atrium Health Levine Cancer Institute
    Charlotte,  NC

    Speakers:

    Angela G. Fleischman , MD,PhD
    University of California, Irvine
    Irvine,  CA

    Raajit K. Rampal , MD, PhD
    Memorial Sloan Kettering Cancer Institute
    New York,  NY

    Harmony Washington , Medscape Oncology
    Email: [email protected]

    Registration for In-Person Program
    Registration for Virtual Program

    Changing the Path of Myelofibrosis: Exploring How We Can Do More for Our Patients

    This program is supported by Morphosys


    3:00 p.m. - 6:00 p.m. Pacific time
    Marriott Marquis San Diego Marina
    Marriott Grand Ballroom 8-9

    Myelofibrosis (MF) is a rare disease that has a significant impact on patient’s quality of life. While many remain symptom-free for years, ultimately symptoms impose a major burden. While Janus kinase (JAK) inhibitors play an important role in treating MF, a variety of novel targeted therapies are in clinical development that have the potential to prevent/delay resistance to ruxolitinib, change the course of the disease, and advance patient outcomes. This interactive symposium will start by providing an overview of the challenges associated with current management from a physician’s perspective followed by an interview with a patient with MF to highlight the challenges that they face. We then continue with a deeper dive into the biological and genetic path of MF, as well as the path of epigenetic dysregulation fueling the development of epigenetic therapies. The session will end with a group discussion reviewing how these new developments may positively impact the evolving journey of patients with MF.

    Chair:

    John Mascarenhas , MD
    Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
    New York,  NY

    Speakers:

    Claire N Harrison
    Guy’s and St. Thomas’ NHS Foundation Trust
    London,  ENG, United Kingdom

    Ronald Hoffman , MD
    Tisch Cancer Institute
    New York,  NY

    Ann Mullally , MD
    Dana-Farber Cancer Institute
    Boston,  MA

    Harmony Washington , Medscape Oncology
    Email: [email protected]

    Registration for In-Person Program
    Registration for Virtual Program

    Complement Wheel: Optimizing Care for Patients with aHUS, HSCT-TMA, and PNH

    This program is supported by Alexion Pharmaceuticals, Inc


    3:00 p.m. - 6:00 p.m. Pacific time
    Marriott Marquis San Diego Marina
    Marriott Grand Ballroom 2-4

    In this live, interactive program, expert faculty will present and discuss the most recent and relevant data and clinical advances as well as provide their expert perspectives around three rare, complex hematologic disorders marked by dysfunction of the complement cascade: atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA). The patient experience using vignettes will be highlighted throughout the event with an emphasis on optimizing clinical decision-making.

    Chair:

    Ilene C. Weitz , MD
    Keck-USC School of Medicine
    Los Angeles,  CA

    Speakers:

    Vincent T. Ho , MD
    Harvard Medical School
    Boston,  MA

    David J Kuter , MD,DPhil
    Massachusetts General Hospital
    Boston,  MA

    Harmony Washington , Medscape Oncology
    Email: [email protected]

    Registration for In-Person Program
    Registration for Virtual Program

    Comprehensive Approaches to Creating Successful Sickle Cell Management Plans Across Patients’ Lifespans

    This program is supported by Vertex Pharmaceuticals


    3:00 p.m. - 6:00 p.m. Pacific time
    San Diego Convention Center
    Room 6B

    This educational activity will explore disease management approaches in SCD by focusing on
    important components of successful pain management, the challenges of complications and
    comorbid conditions in patients with SCD, the changing needs of patients across the lifespan
    including issues pertaining to reproductive and sexual health, and the evolving treatment
    landscape for patients with SCD.

    Chair:

    Biree Andemariam , MD
    University of Connecticut Health
    Farmington,  CT

    Speakers:

    Lydia H Pecker , MD
    Johns Hopkins University School of Medicine
    Baltimore,  MD

    Nirmish Shah , MD
    Duke University Medical Center
    Cary,  NC

    James Palatine , Physicians' Education Resource, LLC
    Email: [email protected]

    Registration for In-Person Program
    Registration for Virtual Program

    Putting Your Stamp on the Next Generation of Care in CML – Improving Outcomes from Frontline to R/R Treatment Settings

    This program is supported by Novartis Pharmaceuticals Corporation


    3:00 p.m. - 6:00 p.m. Pacific time
    Marriott Marquis San Diego Marina
    Pacific Ballroom Salons 24-26

    The live activity will feature a series of didactic presentations coupled with case-based panel discussions and question-and-answer sessions from the audience. Using a blended instructional model of didactic presentations and interactive panel discussions is intended is to improve medical practices and patient care through evidence-based presentations, discussion, and authoritative peer-exchange on important clinical issues. The satellite program will bring together clinical experts to highlight novel agents in the management of frontline and R/R CML, including the latest clinical data and application of novel TKIs and next-generation treatment approaches, including best practices for monitoring and managing adverse events with a multidisciplinary team in the United States and around the world! Considerations for advanced practice professionals, pharmacists and community clinicians will also be addressed throughout the educational event. Based on positive feedback from attendees at the 2022 ASH Friday Satellite Symposia, each presentation will follow with question-and-answer discussion from the floor.

    Chair:

    Jorge Cortes , MD
    Augusta University
    Augusta,  GA

    Speakers:

    Andreas Hochhaus , MD
    Universitätsklinikum Jena
    Jena,  Germany

    Amanda Rodriguez , PA-C
    Moffitt Cancer Center
    Tampa,  FL

    Kelly Donald , Physicians' Education Resource, LLC
    Email: [email protected]

    Registration for In-Person Program
    Registration for Virtual Program

    Real-World Applications of Asparaginase Formulations in ALL and LBL from Pediatric/AYA to Adult Treatment: Maximizing Clinical Benefits Through Multidisciplinary Care

    This program is supported by PER Oncology


    3:00 p.m. - 6:00 p.m. Pacific time
    San Diego Convention Center
    Room 6A

    The live activity will feature a series of didactic presentations coupled with case-based panel discussions and question-and-answer sessions from the audience. Using a blended instructional model of didactic presentations and interactive panel discussions is intended is to improve medical practices and patient care through evidence-based presentations, discussion, and authoritative peer-exchange on important clinical issues. The satellite program will bring together 4 clinical experts to highlight novel agents in the management of ALL/LBL, including the latest clinical data and application of asparaginase formulations across the ALL continuum, including best practices for monitoring and managing hypersensitivity and silent inactivation reactions in the United States and around the world! Considerations for advanced practice professionals and community clinicians will also be addressed throughout the educational event.

    Chair:

    Rachel E. Rau , MD
    Texas Children's Hospital/Baylor College of Medicine
    Houston,  TX

    Speakers:

    Luke Maese , DO
    Huntsman Cancer Institute, University of Utah
    Salt Lake City,  UT

    Etan Orgel , MD
    Keck School of Medicine of University of Southern California
    Los Angeles,  CA

    Kelly Donald , Physicians' Education Resource, LLC
    Email: [email protected]

    Registration for In-Person Program
    Registration for Virtual Program

    Toward a Brighter Future for Preventing COVID-19 in Patients With Hematologic Malignancies: Leveraging the Power of Current Strategies and Next-Generation Agents

    This program is supported by AstraZeneca LP


    3:00 p.m. - 6:00 p.m. Pacific time
    San Diego Convention Center
    Ballroom 20CD

    This CME activity is provided by Penn State College of Medicine and developed with our educational partner, PVI, PeerView Institute for Medical Education.

    This activity is supported by an independent educational grant from AstraZeneca LP.

    Hundreds of thousands of patients with hematologic malignancies in the United States must take medications that leave them immunocompromised. Though vaccinated, these patients have hundred-fold higher rates of serious breakthrough COVID-19 infections compared with healthy individuals because of inadequate responses to vaccination. Tixagevimab/cilgavimab lost its emergency use authorization as prevention for immunocompromised patients because of its lack of efficacy against newer variants. However, next-generation prevention agents are in development, including a new monoclonal antibody, AZD3152. Meanwhile prevention of COVID-19 for immunocompromised people is shifting to a more individualized approach, increasing the complexity of clinical decision-making.

    PeerView's expert faculty will discuss strategies to engage patients with elevated risk of serious COVID-19 infection in the development of customized prevention plans. In addition, they will explore approaches to overcoming real-time barriers to access and use of available options for prevention of serious COVID-19 illness.

    Chair:

    Shmuel Shoham , MD
    Johns Hopkins University School of Medicine
    Baltimore,  MD

    Speakers:

    Ghady Haidar , MD
    University of Pittsburgh and UPMC
    Pittsburgh,  PA

    Carol Ann Huff , MD
    Sidney Kimmel Comprehensive Cancer Center
    Baltimore,  MD

    Leigh Anne Bongiovanni , PVI, PeerView Institute for Medical Education
    Email: [email protected]

    Registration for In-Person Program
    Registration for Virtual Program

  • 4

    Evening Symposia

    7:00 p.m. - 10:00 p.m.
    Pacific time

    BEYOND THE GUIDELINES: Clinical Investigator Perspectives on the Management of Patients with Multiple Myeloma (Part 4 of a 4-part CME-accredited Symposia Series)

    This program is supported by educational grants from Abbvie Inc, GSK, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Karyopharm Therapeutics, Legend Biotech, Regeneron Pharmaceuticals Inc, and Sanofi


    7:00 p.m. - 10:00 p.m. Pacific time
    Omni San Diego
    Grand Ballroom, 4

    This CME-accredited program, offered for in-person and virtual attendees, will focus on the management of multiple myeloma (MM). Five investigators will serve as faculty and the program will be moderated by Dr Neil Love, president of Research To Practice (RTP). Prior to the program, RTP will recruit 15 clinical investigators, who, in addition to the participating faculty, will be asked to complete a case-based survey intended to illuminate their general practice patterns. In addition, RTP will recruit 3 “non-faculty” clinical investigators to participate in video recorded interviews with Dr Neil Love in which they will provide an explanation/justification for their responses to this survey and share the scientific rationale guiding their thinking.

    At the live event, for each module, Dr Love will present results from the case-based survey, followed by video excerpts from the non-faculty member interviews. The faculty panel will then be asked to register their level of agreement/disagreement with their colleagues’ answers and provide perspectives on their own responses. Each faculty member will also deliver a brief PPT presentation focused on reviewing recently published research data and ongoing clinical trials. Clinicians in attendance will have to complete the same survey and present their own questions for discussion.

    Chair:

    Neil Love , MD
    Research To Practice
    Key Biscayne,  FL

    Speakers:

    Amrita Krishnan , MD
    City of Hope
    Irvine,  CA

    Sagar Lonial , MD
    Winship Cancer Institute, School of Medicine, Emory University
    Atlanta,  GA

    Robert Z. Orlowski , MD, PhD
    The University of Texas MD Anderson Cancer Center
    Houston,  TX

    Noopur Raje , MD
    Massachusetts General Hospital Cancer Center
    Boston,  MA

    Paul G. Richardson , MD
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School
    Boston,  MA

    Sylvia Eriksen , Research To Practice
    Email: [email protected]

    Evolving Paradigms: Novel Approaches and Best Practices for Hodgkin Lymphoma

    This program is supported by Bristol Myers Squibb and Seagen


    7:00 p.m. - 10:00 p.m. Pacific time
    Marriott Marquis San Diego Marina
    Marriott Grand Ballroom 11-13

    This 90-minute symposium will feature 3 experts in treating HL and is designed to highlight recent clinical trial data in cHL, real-world outcomes, and provide patient case examples on how to translate these data into clinical practice. Panel discussion and audience polling questions will be interwoven throughout the program to enhance dialogue.

    Harmony Washington , Medscape Oncology
    Email: [email protected]

    How Do We Treat GvHD Today... And Tomorrow? Treatment Algorithms for Key Decision Points in Prophylaxis Care, Acute, and Chronic Disease

    This program is supported by Incyte Corporation; ST Shared Services LLC, a Mallinckrodt company; Equillium Bio


    7:00 p.m. - 10:00 p.m. Pacific time
    Marriott Marquis San Diego Marina
    Pacific Ballroom Salons 24-26

    The live activity will feature a series of didactic presentations coupled with case-based panel discussions and question-and-answer sessions from the audience. Using a blended instructional model of didactic presentations and interactive panel discussions is intended is to improve medical practices and patient care through evidence-based presentations, discussion, and authoritative peer-exchange on important clinical issues. The satellite program will bring together 4 clinical experts to highlight novel agents in the management of acute and chronic GvHD, as well as prophylaxis care. Novel and investigational approaches will be considered across key decision points in care, with ample discussion from the expert panel and from “the floor” on how we treat GvHD today... and tomorrow!

    Chair:

    Corey Cutler
    Dana-Farber Cancer Institute
    Boston,  MA

    Speakers:

    Hannah Choe , MD
    The Ohio State University Wexner Medical Center
    Columbus,  OH

    Carrie L. Kitko
    Vanderbilt University
    Nashville,  TN

    Miguel-Angel Perales , MD
    Memorial Sloan Kettering Cancer Center
    New York,  NY

    Kelly Donald , Physicians' Education Resource, LLC
    Email: [email protected]